RZLT

Rezolute Inc

3.82

Oct 26 • 3:59 PM ET -0.04 (-0.91%)

3.85

Aftermarket • 7:30 PM ET +0.03 (0.84%)

Healthcare Biotechnology USA Small NASD

Peers: MBX AMLX RYTM XERS ASND ENTX SPRB ETON NBIX NVO

| Held by: VTI IWM VXF IWN VTWO DFAS SCHA FESM VFMO JSML

Scroll to Statements

Index	RUT
Market Cap	369.51M
Enterprise Value	262.64M
Income	-77.59M
Sales	0.00M
Book/sh	1.04
Cash/sh	1.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	58
IPO	May 08, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.66
P/C	3.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.68
Current Ratio	9.68
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.75
EPS next Y	-0.52
EPS next Q	-0.19
EPS this Y	5.84%
EPS next Y	26.62%
EPS next 5Y	6.44%
EPS past 3/5Y	9.63% 22.81%
Sales past 3/5Y	- -
EPS Y/Y TTM	23.34%
Sales Y/Y TTM	-
EPS Q/Q	24.14%
Sales Q/Q	-
Earnings	Sep 24 AMC
EPS/Sales Surpr.	-35.23% -

Insider Own	13.96%
Insider Trans	0.00%
Inst Own	93.05%
Inst Trans	0.91%
ROA	-53.82%
ROE	-59.04%
ROIC	-76.85%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.59%
SMA50	-11.16%
SMA200	-0.98%
Trades

Shs Outstand	96.41M
Shs Float	83.22M
Short Float	20.09%
Short Ratio	11.23
Short Interest	16.71M
52W High	11.46 -66.66%
52W Low	1.07 257.01%
Volatility	5.67% 8.42%
ATR (14)	0.30
RSI (14)	41.57
Beta	0.65
Rel Volume	1.04
Avg Volume	1.49M
Volume	1,543,515

Perf Week	3.24%
Perf Month	-2.05%
Perf Quarter	-22.36%
Perf Half Y	15.41%
Perf YTD	61.86%
Perf Year	-58.43%
Perf 3Y	289.80%
Perf 5Y	-41.23%
Perf 10Y	-93.89%
Recom	1.00
Target Price	9.80
Prev Close	3.86
Price	3.82
Change %	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-30-26	Initiated	Lake Street	Buy	$9
Sep-29-26	Upgrade	Craig Hallum	Hold → Buy	$7
Jun-03-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform	$11
Mar-25-26	Upgrade	Wedbush	Neutral → Outperform	$5
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral	$1
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold	$2
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Show Previous Ratings

Oct-14-26 04:05PM	Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire) -8.24% -7.80%
Oct-05-26 08:58AM	Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss Retail Expects Huge Rerating (Stocktwits) +7.98%
07:00AM	Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism (GlobeNewswire)
Sep-24-26 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire)
Sep-09-26 10:43AM	Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint (InvestorsHub) -7.73%
07:00AM	Loading…
07:00AM	Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Sep-02-26 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire)
Jul-21-26 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire) +14.38%
Jun-17-26 07:00AM	Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society (GlobeNewswire)
Jun-04-26 07:30AM	Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society (GlobeNewswire)
Jun-03-26 09:55AM	Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls (The Fly) +14.50%
07:47AM	Rezolutes stock up on interim Phase III tumour HI data (Clinical Trials Arena)
Jun-02-26 07:00AM	Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire) +10.80%
May-12-26 04:05PM	Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
May-11-26 07:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-01-26 12:15PM	Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting (GlobeNewswire)
Apr-21-26 07:00AM	Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting (GlobeNewswire)
Mar-24-26 07:00AM	Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting (GlobeNewswire) +12.08%
Mar-04-26 07:00AM	Rezolute to Participate in the Citizens Life Sciences Conference (GlobeNewswire) +6.15%
Feb-12-26 04:05PM	Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.72% +5.79%
Feb-04-26 07:00AM	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.62%
Jan-14-26 11:58AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +9.68%
Jan-07-26 07:00AM	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism (GlobeNewswire) +23.04%
Dec-31-25 11:12AM	Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing (Insider Monkey) +7.76%
Dec-30-25 04:39PM	Insiders Made Their Bets in 2025-These Were the Top 5 Stocks They Bought (MarketBeat) -9.88%
Dec-23-25 09:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +18.05%
Dec-18-25 01:49PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) -7.96%
Dec-17-25 09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
Dec-15-25 01:06PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm (PR Newswire) -9.44%
09:35AM	Loading…
09:35AM	Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround (Zacks)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) +28.57%
11:52AM	Rezolute stock crashes after sole pipeline candidate fails Phase III (Clinical Trials Arena)
08:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire)
05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 07:59PM	Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure (Business Wire) -87.20%
06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
07:00AM	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks) -5.66%
Nov-12-25 12:00PM	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
09:55AM	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-25 05:30PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.48%
Nov-06-25 04:05PM	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +12.08%
Nov-05-25 07:30AM	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire) +5.06%
Oct-29-25 11:57AM	Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy (Insider Monkey)
Oct-15-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.89%
Oct-09-25 04:05PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Sep-17-25 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.36%
07:05AM	Rezolute Stock: FDA Fast Track Fuels 2025 Breakout (MarketBeat)
Sep-02-25 07:30AM	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire)
Aug-27-25 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 07:30AM	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Jul-22-25 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:30AM	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire) +6.24%
May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans Daron	CFO	Mar 30 '26	Buy	2.85	10,000	28,500	414,462	Mar 31 04:59 PM
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,548	119,675	Dec 17 04:14 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17 04:13 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.77	40,000	70,640	415,900	Dec 15 07:35 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.79	5,000	8,938	7,000	Dec 15 07:35 PM
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15 07:35 PM
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15 07:34 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

FounderMr. Nevan Charles Elam J.D.

M.S.Mr. Daron G. Evans M.B.A.

Chief Medical OfficerDr. Brian Kenneth Roberts M.D.

Senior VP & Head of OperationsMr. Michael R. Deperro

M.D.Dr. Davelyn Eaves Hood M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RZLT

Rezolute Inc

Upgrade your Finviz experience